Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc2102494 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biogenic silver nanoparticle as an adjuvant in an S1 subunit recombinant vaccine.
Braz J Microbiol
January 2025
Center of Technological Development, Biotechnology, Federal University of Pelotas, Pelotas, Rio Grande do Sul, Brazil.
Adjuvants are crucial for maintaining specific, protective, and long-lasting immunity. Here, we aimed to evaluate the antigenic and immunogenic activity of a recombinant form of the S1 domain of the Spike protein, associated with biogenic silver nanoparticles (bio-AgNP) and Alhydrogel as an alternative and conventional adjuvant, respectively, for a SARS-CoV-2 subunit vaccine. We produced and evaluated the antigenicity of the recombinant S1 (rS1) protein by testing its recognition by antibodies present in SARS-CoV-2 positive human serum.
View Article and Find Full Text PDFPoint-of-need diagnostics in a post-Covid world: an opportunity for paper-based microfluidics to serve during syndemics.
Lab Chip
January 2025
Mitos Diagnostics, Inc., California, USA.
Zoonotic outbreaks present with unpredictable threats to human health, food production, biodiversity, national security and disrupt the global economy. The COVID-19 pandemic-caused by zoonotic coronavirus, SARS-CoV2- is the most recent upsurge of an increasing trend in outbreaks for the past 100 years. This year, emergence of avian influenza (H5N1) is a stark reminder of the need for national and international pandemic preparedness.
View Article and Find Full Text PDFAdvances in nucleic acid-based cancer vaccines.
J Biomed Sci
January 2025
National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, 35053, Taiwan.
Nucleic acid vaccines have emerged as crucial advancements in vaccine technology, particularly highlighted by the global response to the COVID-19 pandemic. The widespread administration of mRNA vaccines against COVID-19 to billions globally marks a significant milestone. Furthermore, the approval of an mRNA vaccine for Respiratory Syncytial Virus (RSV) this year underscores the versatility of this technology.
View Article and Find Full Text PDFDesigning of an innovative conserved multiepitope subunit vaccine targeting SARS-CoV-2 glycoprotein and nucleoprotein through immunoinformatic.
Sci Rep
January 2025
Department of Biology, Bahir Dar University, P.O.Box 79, Bahir Dar, Ethiopia.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has imposed substantial challenges on our society due to the COVID-19 pandemic. This virus relies heavily on its surface glycoprotein (S-glycoprotein) to facilitate attachment, fusion, and entry into host cells. While the nucleoprotein (N) in the ribonucleoprotein core binds to the viral RNA genome.
View Article and Find Full Text PDFImmunobiology of MPox Infection and Its Management: Experience From Developing Nations.
Rev Med Virol
January 2025
Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Purpose: As humanity grapples with the COVID-19 pandemic caused by the novel SARS-CoV-2 virus, the rising threats of the MPox virus (MPXV) in 2022 and 2024 have shown signs of global transmission and the potential to spark another pandemic. Though MPXV has been present for over 5 decades, with cases traditionally confined to endemic regions in West and Central Africa, recent outbreaks have occurred in multiple non-endemic regions, declaring itself as a Public Health Emergency of International Concern. This study aims to examine the patterns of MPXV transmission, its zoonotic potential, associated complications, and viable strategies to control its spread.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!